“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"


Compound Indication Phase Partner
SENS-111 Vertigo barre1 Sens111
Phase 1b achieved
Palau Pharma
SENS-218 Vestibular lesions barre2 Sens218
Phase 1b initiated
SENS-300 Drug-induced ototoxicity   barre2